From Variant Detection to Clinical Actionability: Expanding the Clinical Perspective on Targeted NGS Profiling in Breast Cancer.

Plain Language SummaryBreast cancer is not a single disease. Each tumour carries its own set of genetic changes, and reading these changes can help doctors choose the most suitable treatment. A recent study from Ukraine used a modern genetic test to examine tumours from breast cancer patients - one of the first efforts of its kind in that country. It found that certain gene changes were common, especially one that tends to appear in slower-growing, more treatable tumours. In our letter responding to that study, we make one main point: finding a gene change is only the first step. What matters is turning that finding into a real decision about care. Several of the gene changes seen in the study affect the same biological "switch" inside cancer cells, and there are now approved medicines that act specifically on that switch. So these results are not just interesting numbers - for many patients they could point toward a targeted treatment. We also explain why this depends on careful laboratory work. The specialist who examines the tumour must describe each gene change precisely, make sure the test used is reliable, and check whether a change might also run in the family and need genetic counselling. When done carefully, genetic testing can move from simply listing gene changes to genuinely guiding treatment - including for patients in regions where such testing is still new.